Hemostemix Inc.
HMTXF
$0.0661
-$0.0011-1.64%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -28.74% | 11.63% | -51.66% | 97.01% | -44.98% |
| Depreciation & Amortization | -- | -- | -- | -100.00% | -100.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.19% | -8.65% | -70.32% | -24.31% | -61.22% |
| Operating Income | 29.19% | 8.65% | 70.32% | 24.31% | 61.22% |
| Income Before Tax | -20.23% | -78.93% | 62.62% | 20.73% | 69.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.23% | -78.93% | 62.62% | 49.38% | 69.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.23% | -78.93% | 62.62% | 49.38% | 69.12% |
| EBIT | 29.19% | 8.65% | 70.32% | 24.31% | 61.22% |
| EBITDA | 29.19% | 8.62% | 70.32% | 24.32% | 61.21% |
| EPS Basic | -13.04% | -69.23% | 67.74% | 53.21% | 72.62% |
| Normalized Basic EPS | -41.67% | -170.00% | 66.67% | -32.56% | 74.47% |
| EPS Diluted | -13.04% | -69.23% | 67.74% | 53.21% | 72.62% |
| Normalized Diluted EPS | -41.67% | -170.00% | 66.67% | -32.56% | 74.47% |
| Average Basic Shares Outstanding | 3.09% | 7.29% | 14.93% | 8.33% | 14.76% |
| Average Diluted Shares Outstanding | 3.09% | 7.29% | 14.93% | 8.33% | 14.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |